UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Hormono-radiothérapie adjuvante des cancers du sein

Bulletin du cancer, 2009-03, Vol.96 (3), p.285-289

2009

Volltextzugriff (PDF)

Current applications of PET imaging of sex hormone receptors with a fluorinated analogue of estradiol or of testosterone

The quarterly journal of nuclear medicine and molecular imaging, 2015-03, Vol.59 (1), p.4

2015

Volltextzugriff (PDF)

Collaboration méditerranéenne pour la lutte contre le cancer : « le passé est comme s’il n’eût jamais existé

Bulletin du cancer, 2010-04, Vol.97 (4), p.407-408

2010

Volltextzugriff (PDF)

Spécial Maghreb

Bulletin du cancer, 2010, Vol.97 (4)

2010

Volltextzugriff (PDF)

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

The Lancet (British edition), 2019-06, Vol.393 (10191), p.2591-2598

2019

Volltextzugriff (PDF)

P5-10-01: Metabolic Pharmacodynamic Effect Evidenced by 18FDG-PET as a Tool for Early Prediction of Iniparib Efficacy in Metastatic Triple Negative Breast Cancer (MTNBC): A Proof of Concept Study

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.P5-P5-10-01

2011

Volltextzugriff (PDF)

Abstract P6-07-28: The 21-gene assay in the decision impact assessment of ER+, HER2- Breast cancer: A French real life prospective study

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P6-P6-07-28

2017

Volltextzugriff (PDF)

Prevalence and management of oropharyngeal candidiasis in cancer patients: Results of a prospective French multicentric survey

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.e20590-e20590

2009

Volltextzugriff (PDF)

Abstract P5-15-06: Impact of post-progression therapy on overall survival (OS) in the IMELDA randomized phase III trial evaluating the addition of capecitabine (CAP) to maintenance bevacizumab (BEV) for HER2-negative metastatic breast cancer (mBC)

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P5-P5-15-06

2017

Volltextzugriff (PDF)

Abstract OT1-03-01: Chemotherapy-free trastuzumab and pertuzumab in HER2 [+] breast cancer: FDG-PET response-adapted strategy. The PHERGain study

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.OT1-03-01-OT1-03-01

2018

Volltextzugriff (PDF)

Abstract OT1-01-01: IMpassion131: A phase III study comparing 1L atezolizumab with paclitaxel vs placebo with paclitaxel in treatment-naive patients with inoperable locally advanced or metastatic triple negative breast cancer (TNBC)

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.OT1-01-01-OT1-01-01

2018

Volltextzugriff (PDF)

Abstract P6-07-05: Interactions between adipocyte stem cells and normal or tumoral mammary epithelial cells. Potantial role of BRCA status and estrogen pathway

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P6-P6-07-05

2018

Volltextzugriff (PDF)

Synovialosarcomes: Données épidémiologiques et histologiques, facteurs pronostiques et traitement

La Presse médicale (1983), 1997-12, Vol.26 (38), p.1867-1873

1997

Volltextzugriff (PDF)

Adjuvant breast cancer treatment with hormono-radiotherapy

Bulletin du cancer, 2009-03, Vol.96 (3), p.285

2009

Volltextzugriff (PDF)

Abstract P1-13-09: Prognostic relevance of prior endocrine treatments in overall survival (OS) at the time of first line chemotherapy in ER[+]/HER2[-] advanced breast cancer (ABC) patients

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P1-P1-13-09

2016

Volltextzugriff (PDF)

Abstract OT1-02-03: Phase I multicenter clinical trial evaluating the combination of trastuzumab emtansine (T-DM1) and non-pegylated liposomal doxorubicin (NPLD) in HER2-positive metastatic breast cancer (MBC) (MEDOPP038 study)

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.OT1-02-03-OT1-02-03

2017

Volltextzugriff (PDF)

Abstract GS3-07: Clinical utility of circulating tumor cell count as a tool to chose between first line hormone therapy and chemotherapy for ER+ HER2- metastatic breast cancer: Results of the phase III STIC CTC trial

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.GS3-07-GS3-07

2019

Volltextzugriff (PDF)

Abstract P2-16-06: Influence of trastuzumab pre-exposure in non metastatic disease to first line metastatic treatment efficacy including trastuzumab: The University Cancer Center - University Pierre & Marie Curie (IUC-UPMC) experience

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P2-P2-16-06

2013

Volltextzugriff (PDF)

Patients’ experience and physicians strategies for selection of anthracyclines and taxanes sequential treatment in adjuvant breast cancer: The Violayne prospective multicenter survey

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e19620-e19620

2011

Volltextzugriff (PDF)

Abstract P4-12-08: Final efficacy results from a single-arm multicenter phase II study evaluating first-line trastuzumab, bevacizumab, and capecitabine (HAX) therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC)

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P4-P4-12-08

2013

Volltextzugriff (PDF)

Abstract P6-14-01: Final results of the TANIA randomized phase III trial of bevacizumab (BEV) after progression on 1st-line BEV therapy for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P6-P6-14-01

2016

Volltextzugriff (PDF)

Abstract P4-12-11: Patient preference for subcutaneous trastuzumab via handheld syringe versus intravenous infusion in HER2-positive early breast cancer: Cohort 2 of the PrefHer study

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P4-P4-12-11

2013

Volltextzugriff (PDF)

Abstract P6-12-06: Three-year follow up results of a phase II study of neoadjuvant bevacizumab, chemotherapy, and trastuzumab in HER2-positive inflammatory breast cancer: BEVERLY2 study

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P6-P6-12-06

2013

Volltextzugriff (PDF)

Abstract P6-12-08: Serum biomarkers identification using quantitative proteomics in patients with HER2-positive inflammatory breast cancer receiving trastuzumab plus bevacizumab-based chemotherapy (BEVERLY 2 trial)

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P6-P6-12-08

2013

Volltextzugriff (PDF)

P3-14-11: Comparison of Two Nomograms To Predict Pathologic Complete Response to Neoadjuvant Chemotherapy – Evidence That HER2 Positive Tumors Need Specific Predictors

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.P3-P3-14-11

2011

Volltextzugriff (PDF)

1 – 25 von 118

Suche als RSS-Feed

Aktive Filter

KollektionNUS Single-Journal Subscriptions

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(118)
Mit Volltextzugriff
(99)

Publikationsform

Artikel
(117)
Tagungsberichte
(1)

Sprache

Englisch
(79)
Französisch
(41)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Hormono-radiothérapie adjuvante des cancers du sein

Current applications of PET imaging of sex hormone receptors with a fluorinated analogue of estradiol or of testosterone

Collaboration méditerranéenne pour la lutte contre le cancer : « le passé est comme s’il n’eût jamais existé

Spécial Maghreb

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

P5-10-01: Metabolic Pharmacodynamic Effect Evidenced by 18FDG-PET as a Tool for Early Prediction of Iniparib Efficacy in Metastatic Triple Negative Breast Cancer (MTNBC): A Proof of Concept Study

Abstract P6-07-28: The 21-gene assay in the decision impact assessment of ER+, HER2- Breast cancer: A French real life prospective study

Prevalence and management of oropharyngeal candidiasis in cancer patients: Results of a prospective French multicentric survey

Abstract P5-15-06: Impact of post-progression therapy on overall survival (OS) in the IMELDA randomized phase III trial evaluating the addition of capecitabine (CAP) to maintenance bevacizumab (BEV) for HER2-negative metastatic breast cancer (mBC)

Abstract OT1-03-01: Chemotherapy-free trastuzumab and pertuzumab in HER2 [+] breast cancer: FDG-PET response-adapted strategy. The PHERGain study

Abstract OT1-01-01: IMpassion131: A phase III study comparing 1L atezolizumab with paclitaxel vs placebo with paclitaxel in treatment-naive patients with inoperable locally advanced or metastatic triple negative breast cancer (TNBC)

Abstract P6-07-05: Interactions between adipocyte stem cells and normal or tumoral mammary epithelial cells. Potantial role of BRCA status and estrogen pathway

Synovialosarcomes: Données épidémiologiques et histologiques, facteurs pronostiques et traitement

Adjuvant breast cancer treatment with hormono-radiotherapy

Abstract P1-13-09: Prognostic relevance of prior endocrine treatments in overall survival (OS) at the time of first line chemotherapy in ER[+]/HER2[-] advanced breast cancer (ABC) patients

Abstract OT1-02-03: Phase I multicenter clinical trial evaluating the combination of trastuzumab emtansine (T-DM1) and non-pegylated liposomal doxorubicin (NPLD) in HER2-positive metastatic breast cancer (MBC) (MEDOPP038 study)

Abstract GS3-07: Clinical utility of circulating tumor cell count as a tool to chose between first line hormone therapy and chemotherapy for ER+ HER2- metastatic breast cancer: Results of the phase III STIC CTC trial

Abstract P2-16-06: Influence of trastuzumab pre-exposure in non metastatic disease to first line metastatic treatment efficacy including trastuzumab: The University Cancer Center - University Pierre & Marie Curie (IUC-UPMC) experience

Patients’ experience and physicians strategies for selection of anthracyclines and taxanes sequential treatment in adjuvant breast cancer: The Violayne prospective multicenter survey

Abstract P4-12-08: Final efficacy results from a single-arm multicenter phase II study evaluating first-line trastuzumab, bevacizumab, and capecitabine (HAX) therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC)

Abstract P6-14-01: Final results of the TANIA randomized phase III trial of bevacizumab (BEV) after progression on 1st-line BEV therapy for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)

Abstract P4-12-11: Patient preference for subcutaneous trastuzumab via handheld syringe versus intravenous infusion in HER2-positive early breast cancer: Cohort 2 of the PrefHer study

Abstract P6-12-06: Three-year follow up results of a phase II study of neoadjuvant bevacizumab, chemotherapy, and trastuzumab in HER2-positive inflammatory breast cancer: BEVERLY2 study

Abstract P6-12-08: Serum biomarkers identification using quantitative proteomics in patients with HER2-positive inflammatory breast cancer receiving trastuzumab plus bevacizumab-based chemotherapy (BEVERLY 2 trial)

P3-14-11: Comparison of Two Nomograms To Predict Pathologic Complete Response to Neoadjuvant Chemotherapy – Evidence That HER2 Positive Tumors Need Specific Predictors

Aktive Filter

Suchergebnisse filtern